Bliss GVS Pharma is currently trading at Rs. 99.45, up by 0.70 points or 0.71% from its previous closing of Rs. 98.75 on the BSE.The scrip opened at Rs. 98.80 and has touched a high and low of Rs. 99.75 and Rs. 97.90 respectively. So far 12339 shares were traded on the counter.The BSE group `A` stock of face value Rs. 1 has touched a 52 week high of Rs. 183.65 on 02-Apr-2019 and a 52 week low of Rs. 73.90 on 23-Aug-2019.Last one week high and low of the scrip stood at Rs. 140.00 and Rs. 82.50 respectively. The current market cap of the company is Rs. 1025.79 crore.The promoters holding in the company stood at 41.60%, while Institutions and Non-Institutions held 27.76% and 30.64% respectively.Bliss GVS Pharma has completed the commissioning and qualification of Phase-I for its new state of the art multi-product facility situated at Palghar East in Maharashtra. This is the largest manufacturing unit of the company in terms of planned production capacity when completed.It is equipped with state of the art process equipment & utilities with a large part of the manufacturing process automated for enhanced levels of productivity, efficiency & compliance while reducing manual intervention. The unit is spread on an overall area of about 200,000 sq. ft. and is intended to further augment the production capacities for the company.Bliss GVS Pharma is engaged in the manufacture of a wide range of Pessary Formulations, Suppository Formulations, Calcium Preparation, Protein Powders, Iron Preparation, Antibiotics, Analgesic & Antipyretics, Respiratory, Anti-inflammatory, Dermatological Preparations, Anti-Diarrhoeal products.

Bliss GVS Pharma is currently trading at Rs. 102.45, up by 1.20 points or 1.19% from its previous closing of Rs. 101.25 on the BSE.The scrip opened at Rs. 105.90 and has touched a high and low of Rs. 105.90 and Rs. 102.25 respectively. So far 53978 shares were traded on the counter.The BSE group `A` stock of face value Rs. 1 has touched a 52 week high of Rs. 190.00 on 05-Nov-2018 and a 52 week low of Rs. 73.90 on 23-Aug-2019.Last one week high and low of the scrip stood at Rs. 105.10 and Rs. 98.90 respectively. The current market cap of the company is Rs. 1060.35 crore.The promoters holding in the company stood at 41.53%, while Institutions and Non-Institutions held 28.89% and 29.57% respectively.Bliss GVS Pharma’s 70% subsidiary -- Kremoint Pharma has received a compliant certification from the US Food and Drug Administration (USFDA) that was based on the inspection conducted at the company`s facility located at M.I.D.C, Ambernath (East), Thane-District, during the period June 17, 2019-June 20, 2019.Bliss GVS Pharma is engaged in the manufacture of a wide range of Pessary Formulations, Suppository Formulations, Calcium Preparation, Protein Powders, Iron Preparation, Antibiotics, Analgesic & Antipyretics, Respiratory, Anti-inflammatory, Dermatological Preparations, Anti-Diarrhoeal products.

The revenue for the June 2019 quarter is pegged at Rs. 1151.61 millions, about 9.84% up against Rs. 1048.43 millions recorded during the year-ago period.Net profit declined -11.56% to Rs. 239.20 millions from Rs. 270.47 millions.A decline of 385.91 millions was observed in the OP in the quarter ended June 2019 from 400.42 millions on QoQ basis. (Rs. in Million) Quarter ended Year to Date Year ended 201906 201806 % Var 201906 201806 % Var 201903 201803 % Var Sales 1151.61 1048.43 9.84 1151.61 1048.43 9.84 4265.90 2982.94 43.01 Other Income 17.93 131.40 -86.35 17.93 131.40 -86.35 358.13 109.95 225.72 PBIDT 385.91 400.42 -3.62 385.91 400.42 -3.62 1289.13 994.60 29.61 Interest 6.11 9.12 -33.00 6.11 9.12 -33.00 31.52 69.51 -54.65 PBDT 379.80 391.31 -2.94 379.80 391.31 -2.94 1257.61 925.09 35.94 Depreciation 18.66 14.53 28.42 18.66 14.53 28.42 57.48 56.72 1.34 PBT 361.14 376.78 -4.15 361.14 376.78 -4.15 1200.13 868.37 38.20 TAX 121.94 106.31 14.70 121.94 106.31 14.70 455.79 298.22 52.84 Deferred Tax 16.53 -8.91 -285.52 16.53 -8.91 -285.52 1.39 -3.81 -136.48 PAT 239.20 270.47 -11.56 239.20 270.47 -11.56 744.34 570.15 30.55 Equity 103.15 103.15 0.00 103.15 103.15 0.00 103.15 103.15 0.00 PBIDTM(%) 33.51 38.19 -12.26 33.51 38.19 -12.26 30.22 33.34 -9.37

Bliss GVS Pharma is currently trading at Rs. 141.90, up by 1.60 points or 1.14% from its previous closing of Rs. 140.30 on the BSE.The scrip opened at Rs. 140.80 and has touched a high and low of Rs. 143.50 and Rs. 140.00 respectively. So far 133983 shares were traded on the counter.The BSE group `B` stock of face value Rs. 1 has touched a 52 week high of Rs. 230.00 on 02-Jan-2018 and a 52 week low of Rs. 125.00 on 06-Dec-2018.Last one week high and low of the scrip stood at Rs. 148.60 and Rs. 135.00 respectively. The current market cap of the company is Rs. 1461.07 crore.The promoters holding in the company stood at 60.16%, while Institutions and Non-Institutions held 10.62% and 29.21% respectively.Arian Investment has increased its holdings in Bliss GVS Pharma and now aggregating to more than five percent of the shares of the company Bliss GVS. Arian Investment’s holding in the company now stands at 9.22%.Bliss GVS Pharma is a fast-growing Pharmaceutical Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market.

Bliss GVS Pharma is currently trading at Rs. 206.50, up by 3.30 points or 1.62% from its previous closing of Rs. 203.20 on the BSE.The scrip opened at Rs. 211.70 and has touched a high and low of Rs. 211.70 and Rs. 205.00 respectively. So far 129600 shares were traded on the counter.The BSE group `B` stock of face value Rs. 1 has touched a 52 week high of Rs. 230.00 on 02-Jan-2018 and a 52 week low of Rs. 129.00 on 07-Jun-2017.Last one week high and low of the scrip stood at Rs. 216.00 and Rs. 202.85 respectively. The current market cap of the company is Rs. 2125.34 crore.The promoters holding in the company stood at 60.16%, while institutions and non-institutions held 7.73% and 32.11% respectively.Bliss GVS Pharma has decided to divest the step down subsidiary of the company, Bliss GVS Healthcare, Nairobi. This decision has been made essentially to lower dependence on Tender Driven Managed Healthcare business and focus on growing the Pharmaceuticals Business. The Board of the Company at their meeting held on January 11, 2018, considered the same. Bliss GVS Pharma is a fast-growing Pharmaceutical Company with a proven track record of developing, manufacturing and marketing high quality pharmaceutical formulations at affordable prices for the global market.

Bliss GVS Pharma has submitted the Shareholding Pattern for the Period Ended December 31, 2016. The above information is a part of company’s filings submitted to BSE.

Bliss GVS Pharma has informed about the details of voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015 along with Scrutinizers Report.The above information is a part of company’s filings submitted to BSE.

Bliss GVS Pharma has informed that the 31st Annual General Meeting (AGM) of the Company was held on September 14, 2016.The above information is a part of company’s filings submitted to BSE.

Bliss GVS Pharma has informed that the Board Meeting of the Company is scheduled to be held on July 27, 2016, to consider the Un-Audited Financial Results of the Company for the quarter ended June 30, 2016. Further, Pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulation, 2015 read with the provision of the code of fair disclosure of the Company, the trading window of the Company will be closed from July 19, 2016 to July 30, 2016.The above information is a part of company’s filings submitted to BSE.

The Exchange has sought clarification from Bliss GVS Pharma on July 11, 2016, with reference to increase in Price and Volume.The above information is a part of company’s filings submitted to BSE.

Bliss GVS Pharma has informed about standalone financial results and standalone limited review for the period ended December 31, 2015.The above information is a part of company’s filings submitted to BSE.

Bliss GVS Pharma has informed about Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.The above information is a part of company’s filings submitted to BSE.